卡爾蔡司成長睿鏡片 (Zeiss MyoCare)

蔡德中 Der-Chong TsaiTaiwan Speaker 豪雅光學近視控制鏡片 (Hoya MiYOSMART)為減緩兒童近視度數的進展，除了藥物、環境與行為策略，近年來還有多種光學介入方式可供選擇。 而這些光學措施主要是基於「周邊近視性離焦能抑制眼軸伸長」的實驗證據。 其中，DIMS（Defocus Incorporated Multiple Segments）鏡片為目前在臨床上研究最多的框架眼鏡技術。其核心設計為在鏡片中心光學區(直徑為9mm)的周邊，配置 396 個具有正3.5D的鏡片小區塊，形成持續性的近視性離焦刺激，以抑制眼軸增長。多項臨床研究顯示，相較於傳統單焦點眼鏡，DIMS 鏡片在減緩近視進展、控制眼軸伸長以及兒童配戴的耐受性方面均具有顯著優勢。本演講 將討論DIMS對於學齡前近視預防的可行性，並聚焦在對於DIMS反應不理想的個案處理。 卡爾蔡司成長睿鏡片 (Zeiss MyoCare)本演講為卡爾蔡司成長睿鏡片的第二部分，主要報告MyoCare與MyoCare S於歐洲與亞洲兒童族群 多中心、隨機對照臨床試驗結果， 歐洲 CEME 研究納入 234 名 6–13 歲兒童，配戴 MyoCare 一年後，相較單光眼鏡，近視度數進展減少 0.21 D、眼軸增長減少 0.14 mm，並顯著降低快速惡化者的比例（SE > −0.50D/yr：21.1% vs 39.3%）。中國 240 名兒童的雙盲隨機試驗顯示，在 12 個月與 24 個月的追蹤中，MyoCare 與 MyoCare S 均較單光眼鏡能顯著減緩眼軸延長及屈光度近視化的速度。12 個月時，MyoCare 與 MyoCare S 分別減少眼軸延長 41% 與 34%，並減緩近視進展 48% 與 45%。24 個月結果同樣顯示穩定的控制效果，眼軸延長分別減少 38% 與 28%。此外，以「Emmetropic Progression Ratio」分析，兩款鏡片皆能使眼軸生長趨近正視化發展，MyoCare 與 MyoCare S 的比率分別達 70% 與 68%。兩種設計在整體控制效果上相近，亦展現高度安全性與良好配戴順應性。綜合而言，MyoCare 與 MyoCare S鏡片具備良好視力品質，不論在亞洲或歐洲族群皆能有效減緩眼軸生長，使眼球發育更接近正視化軌跡，是目前具跨族群證據支持的近視控制鏡片解決方案。 眼科醫師在校園視力保健及公衛推廣中的角色面對近視狂潮，眼科醫師在校園視力保健與公衛推廣中扮演關鍵角色: Partner, Educator, Advisor。近視防治有兩大策略：延後近視發生（近視預防） 與 減緩進展（近視控制），其中近視控制主要在診間進行，而近視預防則必須走入校園。以宜蘭縣模式為例，由眼科醫師到園所進行散瞳驗光檢查，可達 92% 的大班幼兒篩檢率，顯示其優於學童自行就醫。散瞳驗光能找出視力正常的低度近視與近視前期，凸顯眼科專業在校園篩檢中的必要性。 眼科醫師同時是 宣傳視力保健知識的教育者，除了在校園演講推動「天天戶外 120 分鐘」、近視控制新知等實證策略、支持教師與校護成為對抗近視前線的重要夥伴。我們亦可針對近視前期兒童的家長，透過社群平台以圖像化、影音化內容，精準推廣正確近視衛教，促進高近視風險學童與家長的警覺心與配合度。此外，眼科醫師也能是 政策建言者。過去十多年來，眼科醫師持續協助衛政與教育單位制定重要政策，包括 2009 年全國天天戶外120政策、2013 年北市國小近視篩檢、2014 年宜蘭縣幼兒園到校散瞳驗光、2022 年宜蘭縣近視前期大班轉介方案，以及 2023 年宜蘭縣國小視力紀錄卡向下延伸至幼兒園。本演講將分享眼科醫師在校園視力保健與公衛推廣參與者、教育者與建言者 的三重的角色。

蔡紫薰 Tzu-Hsun TsaiTaiwan Speaker Facts and Myths: What We Need to Know About Atropine Eye DropsA study conducted in Taiwan during the 1990s demonstrated that atropine reduced myopia progression in a dose-dependent manner. Since that time, the clinical use of atropine in school-aged children has been widespread in Taiwan for more than two decades. Owing to this long history of high-concentration atropine prescriptions, Taiwan represents a distinctive setting in which to evaluate the long-term safety of atropine use. Using data from a large cohort within the NHIRD, we found that the incidence of ocular complications was higher among individuals with myopia compared with those without. However, among participants with myopia, the incidence of these complications did not differ between atropine users and nonusers, and higher cumulative doses of atropine were not associated with increased risk. The long-term efficacy of atropine eye drops for myopia control also merits further investigation. The LAMP clinical trial demonstrated that continuous treatment with 0.05% atropine effectively controlled myopia progression over five years. In contrast, the ATLAS from Singapore reported that topical atropine use during childhood was not associated with long-term ocular complications; however, its long-term efficacy in myopia control was less conclusive. Furthermore, recent randomized clinical trials have yielded inconsistent findings regarding the effectiveness of low-dose atropine, and regulatory approval by the U.S. FDA remains pending. Further research is therefore warranted to refine atropine treatment strategies, including the optimal timing of initiation, adjustment of concentration, duration of therapy, and methods and timing of discontinuation. Most importantly, future work should aim to clarify the ultimate clinical significance and long-term benefits of atropine therapy for myopia control. 接軌國際：IMI 近視前期定義與台灣經驗分享Pre-myopia is an emerging concept in myopia prevention, referring to children within a specific age range who exhibit refractive errors that, along with certain risk factors, place them at increased risk of developing myopia and who may benefit from early intervention. This presentation focuses on the international definitions of pre-myopia and utilizes public health survey data and clinical evidence from Taiwan to analyze the prevalence of pre-myopia and explore issues related to myopia development.